News

A new meta-analysis found no improvement in symptoms or in quality of life among more than 2000 participants treated for subclinical disease.

The approval was based on a comprehensive data package demonstrating that Hyrimoz matches the reference biologic in terms of safety, efficacy, and quality.

Findings from the most extensive study to analyze the association between HLA-B27 status and manifestations of AS.

Try this short quiz on the first update to the Endocrine Society practice guideline on hirsutism since 2008.

The US Department of Health and Human Services updated guidelines feature key recommendations for young children aged 3-5, youths aged 6-17, adults, older adults, pregnant and post-partum women, as well as adults with chronic health conditions and disabilities.

Take this 5-question quiz for a quick refresher on the ACR guidelines.

What next when methotrexate monotherapy fails? The answer-and 4 more questions on RA treatment-can be found here.

A look at the relationship between disease activity, progression, and low bone mineral density in axial spondyloarthritis.

Dutch researchers found no need for a gender divide in the diagnostic approach to suspected axSpA.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

Patients with severe scleroderma who were treated with hematopoietic stem cell transplantation showed significant improvement in long-term outcomes such as survival and functional status.

A new study found statin use is associated with a decreased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients. 

Take this 6-question quiz to test your knowledge of current recommendations for CV risk assessment, cancer screening, and immunization in patients with lupus.

New recommendations cover pre-conception assessment, pregnancy-compatible medications, breastfeeding, and contraception for rheumatology patients.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

Answer these 8 questions to test your knowledge of the latest RA research findings.

New guidelines have been drafted for the treatment of JIA, specifically addressing therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis.

The findings led the team to believe a focus on treatment strategy, rather than disease activity, is more indicative of aortic distensibility improvement.

The pros and cons of HCQ dosing guidelines to limit potential eye toxicity were explored at this year’s ACR/ARHP Annual Meeting.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

Obesity in patients with rheumatoid arthritis has been found to influence the effectiveness of JAKi inhibitor treatments.

A patient's genetic predisposition to low bone mineral density can increase their risk for osteoporotic fractures, according to a new genome-wide association study. 

Investigators assessed the risk of developing malignancies or serious infections with JAK inhibitors for RA treatment.

Findings from the first study to incorporate a meta-analysis on TNFi dose adjustment in an axSpA population.

Patients with active rheumatoid arthritis who are cs/bDMARD-naïve may see a greater reduction in pain and improvement in physical function on baricitinib monotherapy compared with monotherapy of tocilizumab or adalimumab.

Seropositivity was strongly associated with ILD risk in this large prospective cohort study.

Periods of moderate-to-vigorous intensity walking (instead of non-walking) was associated with less risk of total knee replacement over 5 years in patients who have, or who are at high risk of, osteoarthritis of the knee.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.

The updated label includes safety and efficacy data about the use of rituximab as follow-up treatment for patients with granulomatosis with polyangiitis and microscopic polyangiitis.

British researchers quantified the burden of continuing weight gain on the risk of PsA.